In contrast, our study indicated that DEFA1/DEFA3 mRNA expression and plasma HNP levels were consistent, hence they should be considered for further cross-sectional or larger cohort studies, including more randomized population groups, to elucidate the feasibility of predictive CHD biomarkers. This evidence concerns the gene DEFA1 and coronary artery disorder.